{"page_content": "ESG R eport 2022\nAt a Glance\nFOUNDED \n2008\nFIRST GENETICALLY DEFINED DISEASE THERAPY APPROVED BY U.S. FDA \nFebruary 2022IPO\nJuly 20131ST APPROVED \nTHERAPIES\n2017 & 2018HEADQUARTERS\nCambridge, Mass.PK ACTIVATION PROGRAMS\nPyruvate Kinase Deficiency, \nThalassemia & Sickle Cell Disease\nWe are fueled by     \n       connections.  \nAgios is a biopharmaceutical company \npassionately committed to improving \nthe lives of people living with genetically \ndefined diseases. \nThe strong bonds we build with patient \ncommunities, healthcare professionals, \npartners and colleagues enrich the \nimpact we have as experts in cellular \nmetabolism. These connections \nenhance our collaboration, creativity  \nand productivity  \u2014 driving our ability  \nto develop life-changing treatments.\nWe are expanding our impact.\nOur pioneering research in PK \nactivation has yielded the first approved \ntherapy for a rare, debilitating, lifelong \nblood disorder as well as a robust \nclinical and preclinical pipeline.We were founded to unlock a new field \nof discovery in cellular metabolism. \nOur first application in IDH inhibition \nresulted in two precision oncology \ntherapies within 10 years. \n4", "metadata": {"source": "NASDAQ_AGIO_2021.pdf", "page": 3, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}